Factors associated with postpartum readmission for hypertensive disorders of pregnancy

Bruce, Kelly H.; Anderson, Meredith; Stark, Joanna D.

doi:10.1016/j.ajogmf.2021.100397

Cited by 27 publications

(24 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intuitively, shorter intervals are more likely to reflect readmissions related to the birth and longer intervals are more likely to be because of unrelated conditions. Most postpartum readmissions cluster within the first 2 weeks, 30,32,57 so the difference between using a 30-day vs 42-day interval is likely small. A small but potentially important bias is introduced by using postbirth intervals rather than postdischarge intervals.…”

Section: Maternal Postpartum Readmission Metricsmentioning

confidence: 99%

Society for Maternal-Fetal Medicine Special Statement: A critique of postpartum readmission rate as a quality metric

Combs¹,

Goffman²,

Pettker³

2022

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

Section: Maternal Postpartum Readmission Metricsmentioning

confidence: 99%

Society for Maternal-Fetal Medicine Special Statement: A critique of postpartum readmission rate as a quality metric

Combs¹,

Goffman²,

Pettker³

2022

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

“…Four patients with GTN at very high risk of liver or brain metastases were reported to be treated with pabolizumab. All patients were treated with pabolizumab 2 mg/kg for 21 d for 5 courses, resulting in complete remission in 3 patients and death due to progression in 1 patient [ 16 ]. Two cases of very high-risk GTN treated with pabolizumab were reported with equally satisfactory results [ 17 ].…”

Section: Immunotherapymentioning

confidence: 99%

Analysis of the Outcome of Treatment of Brain Metastases from Malignant Trophoblastic Tumours and Risk Factors for Prognosis during Pregnancy

Wang

Zhang

2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

Temozolomide combined with whole-brain radiotherapy has good near-term efficacy and safety in the treatment of brain metastases from nonsmall cell lung cancer. In this study, we analyzed the risk factors for treatment and prognosis of brain metastases in gestational trophoblastic neoplasm (GTN) during pregnancy. Thirty-one patients with brain metastases were included in the study. All patients had a pathological diagnosis of primary lesions, including 23 adenocarcinomas, 7 squamous carcinomas, and 1 adenosquamous carcinoma, and had ≥3 intracranial metastases, controlled primary lesions (including resected primary lesions or unresectable primary lesions in partial remission (PR)/complete remission (CR) for ≥2 months) by cranial enhancement MRI and no extracranial metastases. Presence or control of extracranial metastases was for ≥2 months. The common adverse toxic effects were nausea, vomiting, neutropenia, and thrombocytopenia, but most patients tolerated them with symptomatic management.

show abstract

“…Labetalol, hydralazine and nifedipine are commonly used to manage acute HTN during pregnancy with a Cochrane review in 2013 finding no significant differences between the medications for management of acute HTN. After acute HTN is controlled, current American College of Obstetrics and Gynecology guidelines allow permissive HTN (up to 150/100 mmHg) prior to treatment and recommend labetalol as the initial choice for ongoing therapy followed by nifedipine if adequate control is not achieved 7 .…”

Section: Introductionmentioning

confidence: 99%

Postpartum Discharge on Labetalol was Associated with Increase Risk of Readmission for Hypertension Compared with Discharge on Nifedipine

Salman¹,

Mumtaz²,

Noreen³

et al. 2023

PJMHS

View full text Add to dashboard Cite

Introduction: Hypertension complicating pregnancy is common and, when uncontrolled, can have devastating consequences. Objectives: The main objective of the study is to find the postpartum discharge on labetalol was associated with increase risk of readmission for hypertension compared with discharge on nifedipine. Material and methods: This cross-sectional study was conducted in Islam medical college and teaching hospital Sialkot during June 2022 to September 2022. The data was collected with the permission of ethical committee of hospital. Data was collected with the permission of ethical committee of hospital. Participants were randomized to labetalol versus extended release nifedipine using a computerized random number generator. Results: Data was collected from 50 female patients. Baseline maternal characteristics were similar between groups, including age, race, body mass index (BMI), gravidity and parity, rate of twins, and presence of medical comorbidities including chronic hypertension. Data was collected in two groups, one group of labetalol and second group of nifedipine. Practical implication: This study will help us to find the efficacy of both the drugs that we used in the study for the purpose of postpartum hypertension. Conclusion: It is concluded that both oral labetalol and oral extended release nifedipine are effective and well tolerated for management of postpartum hypertension. Keywords: Hypertension, Postpartum, Oral, Management, Labetalol, Nifedipine

show abstract

Factors associated with postpartum readmission for hypertensive disorders of pregnancy

Cited by 27 publications

References 12 publications

Society for Maternal-Fetal Medicine Special Statement: A critique of postpartum readmission rate as a quality metric

Society for Maternal-Fetal Medicine Special Statement: A critique of postpartum readmission rate as a quality metric

Analysis of the Outcome of Treatment of Brain Metastases from Malignant Trophoblastic Tumours and Risk Factors for Prognosis during Pregnancy

Postpartum Discharge on Labetalol was Associated with Increase Risk of Readmission for Hypertension Compared with Discharge on Nifedipine

Contact Info

Product

Resources

About